Table 3 The area of NCI-H295R and SW-13 MCAs treated with various concentrations of bortezomib, oubain, methotrexate and 7.5 μM pyrimethamine was significantly smaller than respective controls
Drugs and concentrations tested in (ratio to IC502) | Area of NCI-H295R MCAs (Mean pixels ± SD) | p-value | Area of SW-13 MCAs (Mean pixels ± SD) | p-value | |
|---|---|---|---|---|---|
Bortezomib | 0.1% DMSO | 2.3 ± 0.7x105 | 0.02 | 8.2 ± 2.4x105 | 0.03 |
3.4 μM 0(10x), | 10.7 ± 0.8x105 |  | 1.0 ± 0.3x105 | ||
0.01% DMSO | 2.6 ± 0.9x105 | 0.048 | 1.1 ± 0.2x106 | 0.02 | |
0.34 μM (1x), | 1.3 ± 0.2x105 |  | 1.8 ± 0.2x105 | ||
0.005% DMSO | 2.3 ± 0.5x105 | 0.01 | 8.3 ± 1.7x105 | 0.015 | |
0.17 μM (0.5x) | 1.3 ± 0.2x105 |  | 1.0 ± 0.2x105 | ||
0.001% DMSO | 3.0 ± 0.6x105 | <0.01 | 7.5 ± 1.2x105 | 0.01 | |
0.03 μM (0.1x) | 1.6 ± 0.1x105 |  | 5.0 ± 1.6x104 | ||
Ouabain | Media only | 2.4 ± 0.07x105 | 0.01 | 1.0 ± 0.2x106 | 0.01 |
0.8 μM (10x) | 1.5 ± 0.1x105 |  | 1.0 ± 0.2x105 | ||
0.16 μM (2x) | 1.6 ± 0.2x105 | 0.03 | 1.4 ± 0.1x105 | 0.01 | |
0.08 μM (1x) | 1.6 ± 0.2x105 | <0.01 | 1.1 ± 0.7x105 | <0.01 | |
Methotrexate | 0.1% DMSO | 2.0 ± 0.2x105 | <0.01 | 7.8 ± 0.5x105 | <0.01 |
2 μM (100x) | 2.3 ± 0.3x104 |  | 1.5 ± 0.7x105 | ||
0.05% DMSO | 1.9 ± 0.6x105 | 0.037 | 6.7 ± 2.0x105 | 0.04 | |
1 μM (50x) | 2.0 ± 0.3x104 |  | 1.3 ± 0.4x105 | ||
0.1% DMSO | 4.3 ± 1.4x105 | <0.01 | 9.2 ± 0.07x105 | 0.01 | |
0.2 μM (10x) | 6.1 ± 4x104 |  | 1.8 ± 0.05x105 | ||
Pyrimethamine | 1% EtOH | 2.4 ± 0.8x105 | <0.01 | 7.0 ± 1.7x105 | 0.01 |
7.5 μM (10x) | 9.3 ± 3.9x104 |  | 1.0 ± 0.2x105 | ||
0.5% EtOH | 1.8 ± 0.1x105 | 0.06 | 7.1 ± 0.6x105 | 0.82 | |
3.7 μM (5x) | 1.3 ± 0.1x105 |  | 7.0 ± 0.7x105 | ||